Where is DICE Therapeutics headquartered?

DICE Therapeutics is located in South San Francisco, CA.

Who invested in DICE Therapeutics?

DICE Therapeutics has 13 investors including Geekdom Fund And Geekdom Fund.

How much funding has DICE Therapeutics raised to date?

DICE Therapeutics has raised ____.

When was the last funding round for DICE Therapeutics?

DICE Therapeutics closed its lastf unding roundon Jul 19, 2017 from a Convertible Note round.

Company Information
Company Timeline (Coming Soon)

dicetherapeutics.com

DICE Therapeutics

Dice Therapeutics is a clinical-stage biopharmaceutical company that makes medicines for chronic autoimmune and inflammatory diseases.

Business Model:

Revenue: $1.1M

Employees: 11-50

DICE Therapeutics was acquired by Eli Lilly.
The acquisition happend on 2023-06-20.
Details of the transaction were not public

Acquirer

Eli Lilly

General Information

Geographic Data

Address: 400 East Jamie Court

City: South San Francisco

State: CA

Zip: 94080

Country: US

Financial Info

Stage:

post ipo equity

Raised Last:

$345M

Raised Total:

$532M

Social

Crunchbase

Metrics

1,701,726Website Global Rank

11,908Website Monthly Traffic

Twitter Followers

Description

DICE Therapeutics is a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. DICE is initially focused on developing oral therapeutics against well-validated targets in immunology, with the goal of achieving comparable potency to their systemic biologic counterparts, which have demonstrated the greatest therapeutic benefit to date in these disease areas. The Company’s DELSCAPE platform is designed to discover selective oral small molecules with the potential to modulate protein-protein interactions (PPIs) as effectively as systemic biologics. DICE’s lead therapeutic candidate, S011806, is an oral antagonist of the pro-inflammatory signaling molecule, interleukin-17 (IL-17), which is a validated drug target implicated in a variety of immunology indications. DICE is also developing oral therapeutic candidates targeting α4ß7 integrin and αVß1/αVß6 integrin for the treatment of inflammatory bowel disease and idiopathic pulmonary fibrosis, respectively.

Contact Phone:
+16505661402

Contact Email:

IPO Details

DICE Therapeutics went public on 9/14/2021 on the NASDAQ

Listed Exchange:
NASDAQ

IPO Date:
9/14/2021

IPO Valuation:
$618M

Ticker Symbol:
DICE

IPO Price:
$17/share

Amount Raised:
$204M

Live

Opened: -/share

EBITDA	-
Total Cash	-
Total Debt	-
Total Revenue	-
Total Profit (Gross)	-
PE Ratio	-

Investments

Announced Date	Company	Transaction	Money Raised

Funding Rounds

Announced Date	Transaction	Number of Investors	Money Raised	Lead Investors
2/2014	Venture Round		$2.9M
9/2021	IPO		$204M
12/2020	Series C		$80M	RA Capital Management Eventide Asset Management New Leaf Venture Partners Soleus Capital Driehaus Capital Management Osage University Partners Asymmetry Capital Management Northpond Ventures Sands Capital Sanofi Ventures Altitude Life Science Ventures Agent Capital
10/2022	Post-IPO Equity		$345M
7/2018	Series B		$50M	Northpond Ventures
1/2014	Private Equity Round	1	-	Miller Investment Management Miller Investment Management
8/2021	Series C	12	$60M	Asymmetry Capital Management Deep Track Capital Driehaus Capital Management Eventide Janus Henderson Investors Logos Capital New Leaf Venture Partners Northpond Ventures OUP (Osage University Partners) RA Capital Management Sands Capital Ventures Soleus Capital Asymmetry Capital Management Deep Track Capital Driehaus Capital Management Eventide Janus Henderson Investors Logos Capital New Leaf Venture Partners Northpond Ventures OUP (Osage University Partners) RA Capital Management Sands Capital Ventures Soleus Capital
6/2015	Venture Round		$4M
1/2021	Series C	13	$80M	Agent Capital Alexandria Venture Investments Altitude Life Science Ventures Asymmetry Capital Management Driehaus Capital Management Eventide New Leaf Venture Partners Northpond Ventures OUP (Osage University Partners) RA Capital Management Sands Capital Ventures Sanofi Ventures Soleus Capital RA Capital Management
10/2022	Post-IPO Equity		$345M
7/2018	Series B	1	$40.5M	Northpond Ventures Northpond Ventures
1/2014	Private Equity Round	1	-	Miller Investment Management Miller Investment Management

Acquisitions

Announced Date	Name	Price

Employee Demographics

Employee Departments

Employee States

Similar Companies

Uniview Singapore VEID	Revenue: 0 - 100000 Employees: Industry: Software	Details
Konkuk University Medical Center	Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education	Details
Daemon Technologies	Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain	Details
Ace International Trade	Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial	Details
An Hòa Communications	Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising	Details